Abstract
Background Liver disease is within the top five causes of premature death in adults. Deaths caused by complications of cirrhosis continue to rise, while deaths related to other non-liver disease areas are declining. Portal hypertension, the primary sequalae of cirrhosis and is associated with the development of variceal haemorrhage, ascites, hepatic encephalopathy and infection, collectively termed hepatic decompensation, that lead to hospitalisation and mortality. It remains uncertain whether administering a non-selective beta-blocker (NSBB), specifically carvedilol, at an earlier stage i.e. when oesophageal varices are small, can prevent VH and reduce all-cause decompensation (ACD).
Methods/design The BOPPP trial is a pragmatic, multicentre, placebo-controlled, triple-blinded, randomised controlled trial (RCT) in England, Scotland, Wales and Northern Ireland. Patients aged 18 years or older with cirrhosis and small oesophageal varices that have never bled will be recruited, subject to exclusion criteria. The trial aims to enrol 740 patients across 55 hospitals in the UK. Patients are allocated randomly on a 1:1 ratio to receive either carvedilol 6.25mg (a NSBB) or a matched placebo, once or twice daily, for 36 months, to attain adequate power to determine the effectiveness of carvedilol in preventing or reducing ACD.
The primary outcome is time to first decompensating event. It is a composite primary outcome made up of variceal haemorrhage (VH, new or worsening ascites, new or worsening hepatic encephalopathy (HE), spontaneous bacterial peritonitis (SBP), hepatorenal syndrome, an increase in Child Pugh grade by 1 grade or MELD score by 5 points, and liver-related mortality. Secondary outcomes include progression to medium or large oesophageal varices, development of gastric, duodenal, or ectopic varices, participant quality of life, healthcare costs and transplant-free survival.
Discussion The BOPPP trial aims to investigate the clinical and cost effectiveness of carvedilol in patients with cirrhosis and small oesophageal varices to determine whether this non-selective beta-blocker can prevent or reduce hepatic decompensation. There is clinical equipoise on whether intervening in cirrhosis, at an earlier stage of portal hypertension, with NSBB therapy is beneficial. Should the trial yield a positive result, we anticipate that the administration and use of carvedilol will become widespread with pathways developed to standardise the administration of the medication in primary care.
Ethics and dissemination The trial has been approved by the National Health Service (NHS) Research Ethics Committee (REC) (reference number: 19/YH/0015). The results of the trial will be submitted for publication in a peer-reviewed scientific journal. Participants will be informed of the results via the BOPPP website (www.boppp-trial.org) and partners in the British Liver Trust (BLT) organisation.
Trial registration EUDRACT reference number: 2018-002509-78
ISRCTN reference number: ISRCTN10324656
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05872698
Funding Statement
The trial was commissioned and is funded by the UK National Institute for Health and Care Research Health Technology Assessment Board (NIHR-HTA): Award ID: 17/32/04 https://www.fundingawards.nihr.ac.uk/award/17/32/04; the funding body was not involved in the data collection and processing, or the writing of this manuscript. The views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The trial has been approved by the National Health Service (NHS) Research Ethics Committee (REC) (reference number: 19/YH/0015).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The main outcomes will be published in a peer-reviewed journal. Unidentifiable participant data will be presented in the trial results. The full study protocol and statistical analysis plans can be requested by email to kch-tr.boppptrial@nhs.net
Abbreviations
- BOPPP
- Beta-blockers or Placebo for Primary Prophylaxis of oesophageal varices
- MBOP
- Mechanism of beta-blockade on bacterial translocation in portal hypertension
- GCP
- Good Clinical Practice
- CI
- Chief Investigator
- CSI
- Chief Scientific Investigator
- CRN
- Clinical Research Network
- TMG
- Trial Management Group
- DMC
- Data Monitoring Committee
- TSC
- Trial Steering Committee
- PPI
- Personal and Public Involvement
- BLT
- British Liver Trust
- NSBB
- Non-selective beta-blocker
- ACD
- All-cause decompensation
- RCT
- Randomised controlled trial
- MELD
- Model for End-Stage Liver Disease
- OV
- Oesophageal varices
- VH
- Variceal Haemorrhage
- NHS
- National Health Service
- REC
- Research Ethics Committee
- MHRA
- Medicines and Healthcare products Regulatory Agency
- CSPH
- Clinically significant portal hypertension
- NICE
- National Institute of Health and Care Excellence
- BSG
- The British Society of Gastroenterology
- COVID-19
- Coronavirus disease
- PREDESCI
- β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension
- SAP
- Statistical Analysis Plan
- HEAP
- Health Economics Analysis Plan
- NIHR
- National Institute for Health and Care Research
- HTA
- Health Technology Assessment
- LPLV
- Last patient last visit
- UK
- United Kingdom
- IGV
- Isolated gastric varices
- GOV
- Gastroesophageal varices
- CTIMP
- Clinical Trial of an Investigational Medicinal Product
- COPD
- Chronic obstructive pulmonary disease
- PIS
- Patient Information Sheet
- KCTU
- King’s Clinical Trials Unit
- IMP
- Investigational Medicinal Products
- GP
- General Practitioner
- aHR
- adjusted hazard ratios
- ITT
- intention-to-treat
- PPP
- per-protocol population
- CONSORT
- Consolidated Standards of Reporting Trials
- NAFLD
- Non-alcoholic fatty liver disease
- LMM
- Linear Mixed Model
- QALY
- quality adjusted life years
- ICER
- incremental cost-effectiveness ratios
- INB
- incremental net health benefit
- CEAC
- cost-effectiveness acceptability curves
- TDF
- Theoretical Domains Framework